Zymeworks Shakes Up Leadership Team as President and COO Neil Klompas Departs

Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company dedicated to developing innovative biotherapeutics, has announced the departure of Neil Klompas, President and Chief Operating Officer. Neil had been a key figure in the growth and development of the company, and his presence will be missed. We thank him for his significant contributions to Zymeworks and wish him all the best in his future endeavors.

Mr. Klompas joined Zymeworks in 2007 as Chief Financial Officer and quickly rose through the ranks, eventually being appointed Chief Operating Officer and President in 2022. During his 15-year tenure, he played an integral role in the development of the Company’s novel multifunctional biotherapeutics, overseeing the finance, legal, business development, human resources, clinical development, and manufacturing departments. His leadership helped lay the foundations for Zymeworks’s success, and has been integral to the Company’s growth.

“We are immensely thankful for Neil’s invaluable contributions to Zymeworks during his long tenure. He has played a vital role in the Company’s progress, from multiple financings and business development activities that led to its initial public offering on the New York Stock Exchange, to subsequent public financings and the collaboration and licensing agreement with Jazz Pharmaceuticals. Neil has provided invaluable support during my first year as Chief Executive Officer, and we wish him the very best in his future endeavors.”

I am filled with immense pride and gratitude for all of the hard work and dedication my colleagues have put forth in the sixteen years since Zymeworks was founded. I am excited to explore new opportunities, but I have full confidence that the talented scientific, technical, and clinical professionals at Zymeworks will continue to make great strides in advancing the Company’s emerging pipeline and creating a positive impact in the lives of those suffering from difficult-to-treat cancers.

Mr. Klompas will be stepping down from his position as President and Chief Operating Officer of the Company on June 30th, 2023, but will remain an advisor to ensure a seamless transition.

About Zymeworks Inc.

Zymeworks Inc. (Nasdaq: ZYME) is a biotechnology company on a mission to make a meaningful difference in people’s lives who are suffering from serious diseases and difficult-to-treat cancers. The company’s innovative therapeutic platforms and drug development engine have enabled them to engineer and develop highly differentiated antibody-based therapeutic candidates.

Zymeworks has recently developed zanidatamab, a HER2-targeted bispecific antibody using Zymeworks’ proprietary Azymetric™ technology, which is being evaluated in global Phase 1, Phase 2, and Phase 3 clinical trials.

The company is also advancing zanidatamab zovodotin (ZW49), a HER2-targeted bispecific antibody-drug conjugate (ADC), and a deep pipeline of other product candidates based on its multispecific antibodies (MSAT) technology. Through strategic partnerships with global biopharmaceutical companies, Zymeworks is committed to making a real impact in people’s lives.

Leave a Comment